Editors' ChoiceCancer Immunotherapy Refining precision immunotherapy Leslie K. FerrarelliScience Signaling, AAAS, Washington, DC 20005, USA. Email: lferrare{at}aaas.org See allHide authors and affiliations Science Signaling 19 Jan 2021:Vol. 14, Issue 666, eabg5661DOI: 10.1126/scisignal.abg5661 Leslie K. Ferrarelli , AAAS, Washington, DC 20005, USA. Email: Find this author on Google Scholar Find this author on PubMed Search for this author on this site For correspondence: lferrare@aaas.org Article Info & Metrics eLetters Two studies show why some, but not all, MMR-deficient tumors are sensitive to immunotherapy.View Full Text
Refining precision immunotherapy By Leslie K. Ferrarelli Science Signaling19 Jan 2021 Two studies show why some, but not all, MMR-deficient tumors are sensitive to immunotherapy.
Refining precision immunotherapy By Leslie K. Ferrarelli Science Signaling19 Jan 2021 Two studies show why some, but not all, MMR-deficient tumors are sensitive to immunotherapy.